In what Commissioner Scott Gottlieb called “a significant milestone” in the FDA’s new policy for oversight of drug compounding , the agency released draft guidance Friday on how it will develop a list of bulk drug substances, known as the 503B list, that outsourcing facilities can use in compounded drugs.
Source: Drug Industry Daily